A Multicenter, Randomized, Double-Masked, Dose-Ranging Study To Compare The Ocular Safety, Tolerability, And Efficacy Of SURF-200 Ophthalmic Solution (0.02% And 0.04% Betamethasone Sodium Phosphate) To Vehicle In Subjects With A Diagnosis Of Dry Eye Disease And Experiencing An Episodic Flare Up
Latest Information Update: 06 Jun 2025
At a glance
- Drugs Betamethasone (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- Sponsors Surface Ophthalmics
Most Recent Events
- 09 Nov 2022 Status changed from active, no longer recruiting to completed.
- 08 Aug 2022 Planned End Date changed from 1 Mar 2023 to 1 Oct 2022.
- 08 Aug 2022 Planned primary completion date changed from 1 Jan 2023 to 1 Oct 2022.